⌘K
t
| TIDM | CIZ |
| Share Price | Loading... |
| Market Cap | Loading... |
Cizzle Biotechnology Holdings PLC announced its Total Voting Rights as of 30 April 2024, in accordance with FCA Rule 5.6.1. The Company's issued ordinary share capital comprises 396,391,773 ordinary shares of 0.01 pence each, each carrying one voting right. With no ordinary shares held in Treasury, the total number of ordinary shares and voting rights stands at 396,391,773.
| Date | 30 Apr 2024 |
| Time | 17:00:00 |
| Category | Capital structure |
| ID | 5879M |
30 April 2024
Cizzle Biotechnology Holdings Plc
("Cizzle Biotechnology" or the "Company")
Total Voting Rights
Cizzle Biotechnology Holdings PLC (LSE: CIZ), the UK based diagnostics developer, makes the following announcement in accordance with Rule 5.6.1 of the Financial Conduct Authority's ("FCA") Disclosure Guidance and Transparency Rules.
As of 30 April 2024, the Company's issued ordinary share capital consists of 396,391,773 ordinary shares of 0.01 pence each, each with one voting right. The Company holds no ordinary shares in Treasury. Therefore, the Company's total number of ordinary shares and voting rights is 396,391,773 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
Enquiries:
|
Cizzle Biotechnology Holdings plc |
Via IFC Advisory |
|
Allan Syms (Executive Chairman) |
|
|
Allenby Capital Limited |
+44(0) 20 33285656 |
|
John Depasquale |
|
|
George Payne |
|
|
Novum Securities Limited |
+44(0) 20 7399 9400 |
|
Colin Rowbury Jon Bellis |
|
|
IFC Advisory Limited |
+44(0) 20 3934 6630 |
|
Tim Metcalfe |
|
|
Florence Chandler |
|
About Cizzle Biotechnology
Cizzle Biotechnology is developing a blood test to facilitate the early detection of lung cancer based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted CIZ1B variant has been shown to be highly correlated with early-stage lung cancer. The Company's proprietary technology results from the work of Professor Coverley and colleagues at the University of York.
For more information please see https://cizzlebiotechnology.com
You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.